Form 4: Alnylam Pharmaceuticals CFO Sells Shares After Performance-Based Stock Unit Vesting

Alnylam Pharmaceuticals' CFO, Jeffrey V. Poulton, sold a portion of his shares following the vesting of a performance-based stock unit, triggered by a positive clinical trial result.

Summary

• Jeffrey V. Poulton, the EVP and Chief Financial Officer of Alnylam Pharmaceuticals, sold shares of the company's common stock.
• The sales occurred on November 26, 2024, following the vesting of a performance-based stock unit (PSU).
• The PSU vested due to the company publicly reporting FDA acceptance of a new drug application for a therapeutic to treat ATTR amyloidosis with cardiomyopathy after a positive Phase 3 clinical trial result.
• A total of 3,434 shares were acquired through the PSU vesting at a price of $0.00.
• Subsequently, 1,682 shares were sold to cover tax obligations at weighted average prices ranging from $247.77 to $252.27.
• The CFO also holds 57 shares indirectly through a managed account.
• The transactions were reported on a Form 4 filing with the SEC.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction following a positive milestone. While the sale of shares might cause some concern, it is primarily driven by tax obligations and is not indicative of a negative outlook. The positive clinical trial result and FDA acceptance are positive signals.

Positives

• The vesting of the performance-based stock unit indicates the achievement of a significant milestone for Alnylam, specifically the FDA acceptance of a new drug application.
• The positive clinical trial result that triggered the vesting suggests progress in the company's drug development pipeline.

Negatives

• The sale of shares by the CFO, even if for tax obligations, could be perceived negatively by some investors.

Risks

• The sale of shares by an executive could create uncertainty among investors.
• The market may react negatively to insider selling, even if it is for tax purposes.

Industry Context

The vesting of the PSU and subsequent sale of shares by the CFO is a common occurrence in the pharmaceutical industry, particularly after positive clinical trial results or regulatory milestones. This event is specific to Alnylam and its stock performance.

Comparison to Industry Standards

• Executive stock sales are a common practice across the pharmaceutical industry, often triggered by vesting events or personal financial planning.
• Companies like Moderna, BioNTech, and Regeneron also see similar patterns of executive stock transactions following significant milestones.
• The sale of shares to cover tax obligations is a standard procedure, and the weighted average prices achieved are within the expected range for such transactions.

Stakeholder Impact

• Shareholders may react to the sale of shares by the CFO, although it is primarily for tax purposes.
• The positive clinical trial result and FDA acceptance are likely to be viewed positively by shareholders.

Key Dates

Keywords

Alnylam Pharmaceuticals, Jeffrey V. Poulton, insider trading, stock sale, performance-based stock unit, PSU, FDA approval, ATTR amyloidosis, clinical trial, Form 4